Carnitine
ApprovedSmall molecule
Carnitine is one of 68 small molecule programs targeting Cardiomyopathy. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Carnitine
UUniversity Health Network, Toronto
Approved
Actemra
RochePreclinical
Cimzia
UCBPreclinical
Simponi
Johnson & JohnsonPreclinical
Enbrel
IImmunex
Preclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ilaris
NovartisPreclinical
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Cataflam
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diabetes1 trial
Carnitine Levels and Carnitine Supplementation in Type I Diabetes
Completed·—··NCT00351234·200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carnitine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details